Saturday, July 12, 2025

Latest

ImmunoPrecise Posts Third Quarter Revenues of $4.0 Million

ImmunoPrecise Antibodies Ltd (TSXV: IPA), a therapeutic antibody and vaccine research company has released its financial results for the third quarter ended on January 31, 2020.

The company had revenues of $4,034,440 in the third quarter, which is a 50% increase from the same quarter in the year prior, with a gross profit of $2,223,669.

Also, for the first time, the company reported a positive adjusted EBITDA of $717,716, which is approximately a 35% increase from the third quarter of the previous year. However, for the 9 months ending on January 31, 2020, ImmunoPrecise reported an EBITDA of $18,356, which is a 98% percent decrease compared to the 9 months ending on January 31, 2019.

Although revenues in the third quarter were positive, ImmunoPrecise did report a net loss of $625,837, which is a 47% decrease from the same quarter of the previous year.

Recently, ImmunoPrecise has joined the efforts in mitigating the coronavirus risk by proactively adjusting its focus towards pressing research and development. The company put in motion programs for developing therapeutics and vaccines for the coronavirus, as well as entered into a collaboration with EVQLV Ltd to increase those development efforts.

ImmunoPrecise is a pharmaceutical research company focused on the development of therapeutic and human monoclonal antibodies for various clients in the medical industry.

ImmunoPrecise Antibodies Ltd is currently trading at $0.68 on the TSX-Venture.


Information for this analysis was found via Sedar and ImmunoPrecise Antibodies Ltd. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Mergers Set the Stage for Uranium’s Growth Cycle | Forum-Baselode Merger

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Recommended

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

Related News

ImmunoPrecise Begins Path to NASDAQ

This morning ImmunoPrecise Antibodies Ltd (TSXV: IPA) announced they have commenced the application process to...

Thursday, September 10, 2020, 09:45:18 AM

ImmunoPrecise Insider Sells $1.9 Million Worth Of Shares Over Three Days

ImmunoPrecise Antibodies Ltd (TSXV: IPA) has seen continued insider selling over the last several days....

Wednesday, September 16, 2020, 12:17:00 PM

Paul Andreola: ImmunoPrecise & Stock Picking In The Small Cap Arena – The Daily Dive

In this episode, we sat down with Paul Andreola, from Smallcap Discoveries, whom is also...

Monday, August 9, 2021, 01:30:00 PM

ImmunoPrecise Antibodies Set To Begin Trading On Nasdaq December 30

ImmunoPrecise Antibodies (TSXV: IPA) (NASDAQ: IPA) has officially been approved for listing on the Nasdaq...

Wednesday, December 23, 2020, 07:50:11 AM

Market Movers: Canadian Small Cap COVID-19 Stocks Take A Beating

COVID-19 related stocks are all the rage this morning, however it appears to be for...

Monday, November 9, 2020, 10:56:07 AM